京新药业(002020) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,060,660,180.25, representing a 10.44% increase compared to CNY 960,425,636.79 in the same period last year[15] - Net profit attributable to shareholders for Q1 2024 was CNY 171,207,841.45, up 13.23% from CNY 151,198,043.53 year-on-year[15] - The total comprehensive income for the current period is 173,496,532.07 CNY, compared to 151,899,910.63 CNY in the previous period, indicating an increase of about 14.2%[27] - The net profit for the first quarter of 2024 was RMB 173,212,132.61, compared to RMB 151,748,477.91 in the previous year, representing a growth of 14.1%[39] Cash Flow - The net cash flow from operating activities increased by 77.76% to CNY 353,529,027.32, compared to CNY 198,885,534.01 in the previous year[15] - The net cash flow from operating activities for the current period is 353,529,027.32 CNY, a significant increase of 77.76% from 198,885,534.01 CNY in the previous period, primarily due to increased sales collections[32] - The net cash flow from investing activities shows a negative value of 295,293,598.31 CNY, a drastic change from -257,496,231.46 CNY in the previous period, mainly due to external investments and long-term asset inputs[32] - The net cash flow from financing activities is 48,665,662.75 CNY, compared to -16,034,763.82 CNY in the previous period, indicating a substantial increase due to increased bill financing[32] Assets and Liabilities - The total assets at the end of Q1 2024 were CNY 8,329,814,292.57, a 4.30% increase from CNY 7,986,556,907.16 at the end of the previous year[15] - The total liabilities increased to RMB 2,615,762,455.48 from RMB 2,446,401,602.14, marking an increase of 6.9%[39] - The equity attributable to shareholders was CNY 5,683,856,610.17, which is a 3.11% increase from CNY 5,512,374,486.23 at the end of the previous year[15] - The equity attributable to the owners of the parent company rose to RMB 5,683,856,610.17 from RMB 5,512,374,486.23, reflecting an increase of 3.1%[39] Expenses - The company's management expenses increased by 30.53% to CNY 52,083,952.53, mainly due to higher depreciation costs[6] - Research and development expenses for the first quarter of 2024 amounted to RMB 98,380,244.05, an increase of 21.7% from RMB 80,838,157.33 in the same quarter last year[39] - The total operating costs for the first quarter of 2024 were RMB 870,669,357.50, up from RMB 805,167,987.13, reflecting a year-on-year increase of 8.1%[39] Other Income and Compensation - The company reported a decrease in investment income by 48.62% to CNY 1,793,438.35, primarily due to reduced interest income from structured deposits[6] - The company announced a performance compensation payment of CNY 2,400,100 due to unmet performance commitments by Sha Xi Pharmaceutical[21] - The company received government subsidies amounting to 11,686,199.07 CNY during the reporting period[30] - The non-operating income for the current period totals 14,266,304.45 CNY after tax effects and minority interests[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 30,747, with the largest shareholder holding 20.77% of the shares[32] - The company has received partial performance compensation of RMB 2,038,400.00 as of April 23, 2024, from its performance commitment obligations[34] Market Strategy - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[40]